Arginine

SCHEMBL2197566

CC(C)C[C@H](N)C(=O)O.CC(C)[C@H](N)C(=O)O.CSCC[C@H](N)C(=O)O.C[C@H](N)C(=O)O.C[C@H](N)C(=O)OC(=O)[C@@H](N)Cc1ccccc1.C[C@H](N)C(=O)OC[C@H](N)C(=O)O.N=C(N)NCCC[C@H](N)C(=O)O.N=C(N)NCCC[C@H](N)C(=O)O.N=C(N)NCCC[C@H](N)C(=O)O.NC(=O)CC[C@H](N)C(=O)O.NCCCC[C@H](N)C(=O)O.N[C@@H](CC(=O)O)C(=O)O.N[C@@H](CC(=O)O)C(=O)O.N[C@@H](CCC(=O)O)C(=O)O.N[C@@H](CCC(=O)O)C(=O)O.N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	TFPI	P10646	1/20	0.36

▸	PTH1R	Q03431	8/20	0.36

▸	GLP1R	P43220	1/20	0.35

▸	GCGR	P47871	1/20	0.35

▸	GIPR	P48546	1/20	0.35

▸	KEAP1	Q14145	2/20	0.34

▸	IL23R	Q5VWK5	1/20	0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Glutamine SCHEMBL2502331	0.91	THRB (0.36)	—
Arginine SCHEMBL16797281	0.85	NPY4R (0.36)	—
Arginine SCHEMBL7211146	0.82	GLP1R (0.35)	PTH1RGLP1R
Arginine SCHEMBL28458140	0.81	FNTA (0.42)	—
Arginine SCHEMBL8082095	0.80	NPY4R (0.37)	TFPIKEAP1
Arginine SCHEMBL17967701	0.79	NPY4R (0.36)	TFPI
Arginine SCHEMBL27486583	0.79	NPY4R (0.44)	—
Phenylalanine SCHEMBL2502333	0.79	BACE1 (0.40)	—
Arginine SCHEMBL28620239	0.79	NPY4R (0.42)	—
Phenylalanine SCHEMBL9714782	0.78	ANPEP (0.39)	—

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-2114942-B1	NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS	MSD KK (JP)	2012-10-31	—	—	EP	disclosed
US-7977336-B2	Aminopyrimidine derivatives as PLK1 inhibitors	BANYU PHARMACEUTICAL CO. LTD (JP)	2011-07-12	—	—	US	disclosed
EP-2116543-A1	NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR	BANYU PHARMACEUTICAL CO., LTD. (JP)	2009-11-11	—	—	EP	disclosed
US-20080305081-A1	Novel aminopyrimidine derivatives as PLK1 inhibitors	BANYU PHARMACEUTICAL CO., LTD. (JP)	2008-12-11	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20080305081-A1	Novel aminopyrimidine derivatives as PLK1 inhibitors	PLK1, AURKA, CDK1	TFPI 3357/4885PTH1R 4149/4885GLP1R 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.